Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome
Abstract Background Chimeric antigen receptor CAR-T cell therapies have ushered in a new era of treatment for specific blood cancers, offering unparalleled efficacy in cases of treatment resistance or relapse. However, the emergence of cytokine release syndrome (CRS) as a side effect poses a challen...
Huvudupphovsmän: | , , , , , , , , |
---|---|
Materialtyp: | Artikel |
Språk: | English |
Publicerad: |
BMC
2024-01-01
|
Serie: | Journal of Translational Medicine |
Ämnen: | |
Länkar: | https://doi.org/10.1186/s12967-023-04779-z |